Galectin‑9 ameliorates fulminant liver injury

Tadokoro,Tomoko; Morishita,Asahiro; Sakamoto,Teppei; Fujihara,Shintaro; Fujita,Koji; Mimura,Shima; Oura,Kyoko; Nomura,Takako; Tani,Joji; Yoneyama,Hirohito; Iwama,Hisakazu; Himoto,Takashi; Niki,Toshiro; Hirashima,Mitsuomi; Masaki,Tsutomu

doi:10.3892/mmr.2017.6606

Galectin‑9 ameliorates fulminant liver injury

Authors:
- Tomoko Tadokoro
- Asahiro Morishita
- Teppei Sakamoto
- Shintaro Fujihara
- Koji Fujita
- Shima Mimura
- Kyoko Oura
- Takako Nomura
- Joji Tani
- Hirohito Yoneyama
- Hisakazu Iwama
- Takashi Himoto
- Toshiro Niki
- Mitsuomi Hirashima
- Tsutomu Masaki
View Affiliations

Affiliations: Department of Gastroenterology and Neurology, Faculty of Medicine, Kagawa University, Kagawa 761‑0793, Japan, Life Science Research Center, Faculty of Medicine, Kagawa University, Kagawa 761‑0793, Japan, Department of Medical Technology, Kagawa Prefectural University of Health Sciences, Kagawa 761‑0123, Japan, Department of Immunology and Immunopathology, Faculty of Medicine, Kagawa University, Kagawa 761‑0793, Japan
Published online on: May 18, 2017 https://doi.org/10.3892/mmr.2017.6606
Pages: 36-42
Copyright: © Tadokoro et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Fulminant hepatitis is a severe liver disease resulting in hepatocyte necrosis. Galectin‑9 (Gal‑9) is a tandem‑repeat‑type galectin that has been evaluated as a potential therapeutic agent for various diseases that regulate the host immune system. Concanavalin A (ConA) injection into mice results in serious, immune‑mediated liver injury similar to human viral, autoimmune and fulminant hepatitis. The present study investigated the effects of Gal‑9 treatment on fulminant hepatitis in vivo and the effect on the expression of microRNAs (miRNAs), in order to identify specific miRNAs associated with the immune effects of Gal‑9. A ConA‑induced mouse hepatitis model was used to investigate the effects of Gal‑9 treatment on overall survival rates, liver enzymes, histopathology and miRNA expression levels. Histological analyses, TUNEL assay, immunohistochemistry and miRNA expression characterization, were used to investigate the degree of necrosis, fibrosis, apoptosis and infiltration of neutrophils and macrophages. Overall survival rates following ConA administration were significantly higher in Gal‑9‑treated mice compared with control mice treated with ConA + PBS. Histological examination revealed that Gal‑9 attenuated hepatocellular damage, reduced local neutrophil infiltration and prevented the local accumulation of macrophages and liver cell apoptosis in ConA‑treated mice. In addition, various miRNAs induced by Gal‑9 may contribute to its anti‑apoptotic, anti‑inflammatory and pro‑proliferative effects on hepatocytes. The results of the present study demonstrate that Gal‑9 may be a candidate therapeutic target for the treatment of fulminant hepatitis.

View Figures

View References

1	Fujiwara K, Mochida S, Matsui A, Nakayama N, Nagoshi S and Toda G: Intractable Liver Diseases Study Group of Japan: Fulminant hepatitis and late onset hepatic failure in Japan. Hepatol Res. 38:646–657. 2008. View Article : Google Scholar : PubMed/NCBI
2	Kern M, Popov A, Scholz K, Schumak B, Djandji D, Limmer A, Eggle D, Sacher T, Zawatzky R, Holtappels R, et al: Virally infected mouse liver endothelial cells trigger CD8+ T-cell immunity. Gastroenterology. 138:336–346. 2010. View Article : Google Scholar : PubMed/NCBI
3	Fujiwara K, Yasui S, Yonemitsu Y, Arai M, Kanda T, Nakano M, Oda S and Yokosuka O: Fixed point observation of etiology of acute liver failure according to the novel Japanese diagnostic criteria. J Hepatobiliary Pancreat Sci. 22:225–229. 2015. View Article : Google Scholar : PubMed/NCBI
4	Ikegami T, Taketomi A, Soejima Y, Yoshizumi T, Sanefuji K, Kayashima H, Shimada M and Maehara Y: Living donor liver transplantation for acute liver failure: A 10-year experience in a single center. J Am Coll Surg. 206:412–418. 2008. View Article : Google Scholar : PubMed/NCBI
5	Saita N, Goto E, Yamamoto T, Cho I, Tsumori K, Kohrogi H, Maruo K, Ono T, Takeya M, Kashio Y, et al: Association of galectin-9 with eosinophil apoptosis. Int Arch Allergy Immunol. 128:42–50. 2002. View Article : Google Scholar : PubMed/NCBI
6	Zhu C, Anderson AC, Schubart A, Xiong H, Imitola J, Khoury SJ, Zheng XX, Strom TB and Kuchroo VK: The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol. 6:1245–1252. 2005. View Article : Google Scholar : PubMed/NCBI
7	Oomizu S, Arikawa T, Niki T, Kadowaki T, Ueno M, Nishi N, Yamauchi A and Hirashima M: Galectin-9 suppresses Th17 cell development in an IL-2-dependent but Tim-3-independent manner. Clin Immunol. 143:51–58. 2012. View Article : Google Scholar : PubMed/NCBI
8	Seki M, Oomizu S, Sakata KM, Sakata A, Arikawa T, Watanabe K, Ito K, Takeshita K, Niki T, Saita N, et al: Galectin-9 suppresses the generation of Th17, promotes the induction of regulatory T cells, and regulates experimental autoimmune arthritis. Clin Immunol. 127:78–88. 2008. View Article : Google Scholar : PubMed/NCBI
9	Niki T, Tsutsui S, Hirose S, Aradono S, Sugimoto Y, Takeshita K, Nishi N and Hirashima M: Galectin-9 is a high affinity IgE-binding lectin with anti-allergic effect by blocking IgE-antigen complex formation. J Biol Chem. 284:32344–32352. 2009. View Article : Google Scholar : PubMed/NCBI
10	Kageshita T, Kashio Y, Yamauchi A, Seki M, Abedin MJ, Nishi N, Shoji H, Nakamura T, Ono T and Hirashima M: Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance. Int J Cancer. 99:809–816. 2002. View Article : Google Scholar : PubMed/NCBI
11	Zamore PD and Haley B: Ribo-gnome: The big world of small RNAs. Science. 309:1519–1524. 2005. View Article : Google Scholar : PubMed/NCBI
12	Chen JF, Mandel EM, Thomson JM, Wu Q, Callis TE, Hammond SM, Conlon FL and Wang DZ: The role of microRNA-1 and microRNA-133 in skeletal muscle proliferation and differentiation. Nat Genet. 38:228–233. 2006. View Article : Google Scholar : PubMed/NCBI
13	Bala S, Marcos M and Szabo G: Emerging role of microRNAs in liver diseases. World J Gastroenterol. 15:5633–5640. 2009. View Article : Google Scholar : PubMed/NCBI
14	Miyoshi H, Kato K, Iwama H, Maeda E, Sakamoto T, Fujita K, Toyota Y, Tani J, Nomura T, Mimura S, et al: Effect of the anti-diabetic drug metformin in hepatocellular carcinoma in vitro and in vivo. Int J Oncol. 45:322–332. 2014.PubMed/NCBI
15	Morishita A and Masaki T: miRNA in hepatocellular carcinoma. Hepatol Res. 45:128–141. 2015. View Article : Google Scholar : PubMed/NCBI
16	Japan Society of Clinical Chemistry, . Recommendation for measuring enzyme activity in human serum. Lactate dehydrogenase (1989–08-30). Japanese Journal of Clinical Chemistry. 19:228–246. 1990.
17	Cortez KJ and Kottilil S: Beyond interferon: Rationale and prospects for newer treatment paradigms for chronic hepatitis C. Ther Adv Chronic Dis. 6:4–14. 2015. View Article : Google Scholar : PubMed/NCBI
18	European Association For The Study Of The Liver: EASL clinical practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol. 57:167–185. 2012. View Article : Google Scholar : PubMed/NCBI
19	European Association for Study of Liver: EASL clinical practice guidelines: Management of hepatitis C virus infection. J Hepatol. 60:392–420. 2014. View Article : Google Scholar : PubMed/NCBI
20	Bockmann JH, Dandri M, Lüth S, Pannicke N and Lohse AW: Combined glucocorticoid and antiviral therapy of hepatitis B virus-related liver failure. World J Gastroenterol. 21:2214–2219. 2015.PubMed/NCBI
21	Sabatos CA, Chakravarti S, Cha E, Schubart A, Sánchez-Fueyo A, Zheng XX, Coyle AJ, Strom TB, Freeman GJ and Kuchroo VK: Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance. Nat Immunol. 4:1102–1110. 2003. View Article : Google Scholar : PubMed/NCBI
22	Lv K, Zhang Y, Zhang M, Zhong M and Suo Q: Galectin-9 ameliorates Con A-induced hepatitis by inducing CD4(+)CD25(low/int) effector T-Cell apoptosis and increasing regulatory T cell number. PLoS One. 7:e483792012. View Article : Google Scholar : PubMed/NCBI
23	Uchida Y, Ke B, Freitas MC, Yagita H, Akiba H, Busuttil RW, Najafian N and Kupiec-Weglinski JW: T-cell immunoglobulin mucin-3 determines severity of liver ischemia/reperfusion injury in mice in a TLR4-dependent manner. Gastroenterology. 139:2195–2206. 2010. View Article : Google Scholar : PubMed/NCBI
24	Hirao H, Uchida Y, Kadono K, Tanaka H, Niki T, Yamauchi A, Hata K, Watanabe T, Terajima H and Uemoto S: The protective function of galectin-9 in liver ischemia and reperfusion injury in mice. Liver Transpl. 21:969–981. 2015. View Article : Google Scholar : PubMed/NCBI
25	Mita E, Hayashi N, Iio S, Takehara T, Hijioka T, Kasahara A, Fusamoto H and Kamada T: Role of Fas ligand in apoptosis induced by hepatitis C virus infection. Biochem Biophys Res Commun. 204:468–474. 1994. View Article : Google Scholar : PubMed/NCBI
26	Feldstein AE, Canbay A, Angulo P, Taniai M, Burgart LJ, Lindor KD and Gores GJ: Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology. 125:437–443. 2003. View Article : Google Scholar : PubMed/NCBI
27	Fujita K, Iwama H, Sakamoto T, Okura R, Kobayashi K, Takano J, Katsura A, Tatsuta M, Maeda E, Mimura S, et al: Galectin-9 suppresses the growth of hepatocellular carcinoma via apoptosis in vitro and in vivo. Int J Oncol. 46:2419–2430. 2015.PubMed/NCBI
28	Kobayashi K, Morishita A, Iwama H, Fujita K, Okura R, Fujihara S, Yamashita T, Fujimori T, Kato K, Kamada H, et al: Galectin-9 suppresses cholangiocarcinoma cell proliferation by inducing apoptosis but not cell cycle arrest. Oncol Rep. 34:1761–1770. 2015.PubMed/NCBI
29	Kanitz A, Imig J, Dziunycz PJ, Primorac A, Galgano A, Hofbauer GF, Gerber AP and Detmar M: The expression levels of microRNA-361-5p and its target VEGFA are inversely correlated in human cutaneous squamous cell carcinoma. PLoS One. 7:e495682012. View Article : Google Scholar : PubMed/NCBI
30	Wang HW, Lo HH, Chiu YL, Chang SJ, Huang PH, Liao KH, Tasi CF, Wu CH, Tsai TN, Cheng CC and Cheng SM: Dysregulated miR-361-5p/VEGF axis in the plasma and endothelial progenitor cells of patients with coronary artery disease. PLoS One. 9:e980702014. View Article : Google Scholar : PubMed/NCBI
31	Haywood L, McWilliams DF, Pearson CI, Gill SE, Ganesan A, Wilson D and Walsh DA: Inflammation and angiogenesis in osteoarthritis. Arthritis Rheum. 48:2173–2177. 2003. View Article : Google Scholar : PubMed/NCBI
32	Xu C, Lu Y, Pan Z, Chu W, Luo X, Lin H, Xiao J, Shan H, Wang Z and Yang B: The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci. 120:3045–3052. 2007. View Article : Google Scholar : PubMed/NCBI
33	Li QJ, Chau J, Ebert PJ, Sylvester G, Min H, Liu G, Braich R, Manoharan M, Soutschek J, Skare P, et al: miR-181a is an intrinsic modulator of T cell sensitivity and selection. Cell. 129:147–161. 2007. View Article : Google Scholar : PubMed/NCBI
34	Raisch J, Darfeuille-Michaud A and Nguyen HT: Role of microRNAs in the immune system, inflammation and cancer. World J Gastroenterol. 19:2985–2996. 2013. View Article : Google Scholar : PubMed/NCBI
35	Li G, Yu M, Lee WW, Tsang M, Krishnan E, Weyand CM and Goronzy JJ: Decline in miR-181a expression with age impairs T cell receptor sensitivity by increasing DUSP6 activity. Nat Med. 18:1518–1524. 2012. View Article : Google Scholar : PubMed/NCBI
36	Pan C, Chen H, Wang L, Yang S, Fu H, Zheng Y, Miao M and Jiao B: Down-regulation of MiR-127 facilitates hepatocyte proliferation during rat liver regeneration. PLoS One. 7:e391512012. View Article : Google Scholar : PubMed/NCBI